Colorectal Cancer Treatment in Hyderabad
Reviewed May 2026 · Dr. Madhav Danthala
Colorectal cancer is the fastest-growing cancer in young adults in Indian metros. The screening age is 45, not 50. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted therapy, and immunotherapy at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.
When to See a Doctor
Most causes of these symptoms are benign — most rectal bleeding is haemorrhoids. The pattern that matters is when something is new, persistent, or accompanied by other warning signs.
Dr. Danthala's Approach
Colorectal cancer treatment in 2026 is increasingly molecularly guided. Three principles shape every consultation.
-
Molecular profiling first
MSI status, KRAS, NRAS, BRAF, and HER2 are tested at diagnosis to guide therapy choice and identify candidates for immunotherapy.
-
More than one path
For rectal cancer, total neoadjuvant therapy and watch-and-wait protocols are increasingly defensible alternatives to immediate surgery in selected patients.
-
Clear, structured communication
Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries.
Treatment Options
Colorectal cancer treatment depends on three things: stage, location (colon vs rectum), and molecular profile (MSI, KRAS, BRAF, HER2). Below are the major modalities patients should expect to see in a treatment plan.
Hemicolectomy, low anterior resection, total mesorectal excision
For colon cancer, the standard surgery is right or left hemicolectomy with regional lymphadenectomy. Rectal cancer requires total mesorectal excision (TME), often with low anterior resection or, less commonly, abdominoperineal resection. Laparoscopic and robotic approaches are routine and reduce recovery time. Sphincter-preserving surgery is the goal whenever oncologically safe.
FOLFOX, CAPOX adjuvant — FOLFIRI for advanced disease
Stage III colon cancer benefits from adjuvant chemotherapy with FOLFOX or CAPOX (3 to 6 months, often 3 months for low-risk per IDEA trial). For metastatic disease, FOLFIRI or FOLFOX combined with biologics is standard. Triplet regimens (FOLFOXIRI) are reserved for fit patients with high tumour burden.
Anti-EGFR, anti-VEGF, anti-HER2, BRAF combinations
Cetuximab and panitumumab (anti-EGFR) are options for KRAS/NRAS/BRAF wild-type left-sided tumours. Bevacizumab (anti-VEGF) adds benefit across most regimens. BRAF V600E mutations are treated with encorafenib + cetuximab. HER2-amplified disease responds to trastuzumab + tucatinib. Molecular profiling at diagnosis is essential to identify these options.
Pembrolizumab for MSI-high; chemoradiation for rectal
For MSI-high (~15% of colorectal cancers), pembrolizumab is now first-line for advanced disease (KEYNOTE-177) and increasingly used in early-stage as neoadjuvant therapy with remarkable response rates. For rectal cancer, total neoadjuvant therapy (chemo + chemoradiation before surgery) and watch-and-wait protocols for complete clinical responders are emerging as alternatives to immediate surgery.
Treatment is shaped by stage, location, molecular profile, and patient preference. The list above is the menu. The right plan is built with the patient in the room.
Frequently Asked Questions
At what age should I start colonoscopy screening in India?
The recommended screening age was lowered from 50 to 45 in 2021 and has been adopted globally including in India. Young-onset colorectal cancer (under 50) is now the fastest-growing cancer in some Indian metros.
Does blood in stool always mean cancer?
No. The most common cause is haemorrhoids. However, persistent or recurrent blood — especially in anyone over 45, or with changes in bowel habits, weight loss, or anaemia — should be evaluated promptly.
What is MSI-high colon cancer?
MSI-high describes a tumour with defective DNA-repair machinery. About 15% of colon cancers are MSI-high. These respond exceptionally well to immunotherapy. MSI status should be tested in all colorectal cancers at diagnosis.
When should I start screening earlier than 45?
If a first-degree relative had colorectal cancer (start at 40 or 10 years before their diagnosis), with inflammatory bowel disease, previous adenomatous polyps, or hereditary syndromes like Lynch syndrome. Lynch syndrome also raises lifetime risk of ovarian, stomach, and endometrial cancers — genetic counselling guides surveillance across all of them, not just the bowel.
What does treatment usually involve?
Early-stage colon cancer: surgery, sometimes followed by chemotherapy. Rectal cancer: often combined chemoradiation followed by surgery. Advanced disease: chemotherapy plus targeted therapy or immunotherapy depending on molecular profile.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Colorectal Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Colorectal Cancer US National Cancer Institute clinical treatment summaries.
From our blog
- Why Colonoscopy Now Starts at 45, Not 50 The screening age moved for a reason. Who should start even earlier, and why colonoscopy still beats FIT for prevention.
- Your Mother's Medical History Is Your Screening Map Lynch syndrome connects colorectal cancer to ovarian and gastric — the right family question shifts the screening calendar by years.
- The Two-Oncologist Rule: When to Get a Second Opinion Rectal cancer (TNT vs. watch-and-wait) is one of the clearest cases for a second opinion in modern oncology.